Skip to main content

Table 4 Outcomes with dabigatran compared with warfarin

From: Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

End points

Dabigatran 110 mg ×2

Dabigatran 150 mg ×2

Warfarin

NNT/NNH: dabigatran 110 mg

NNT/NNH: dabigatran 150 mg

Primary outcomes (%)

1.53

1.11

1.69

625

172

Myocardial infarction (%)

0.7

0.7

0.5

500

500

Mortality (%)

3.8

3.6

4.1

330

200

Major bleeding (%)

2.7

3.1

3.4

143

333

Intracranial bleeding (%)

0.2

0.3

0.7

200

250

Net clinical benefits (%)

7.1

6.9

7.6

200

143

  1. NNH, number needed to harm; NNT, number needed to treat. Net clinical benefits: vascular events, death and major bleeding. Data from the RE-LY trial [16].